Adjuvant Systemic Hypothermia During Mechanical Thrombectomy (ReCCLAIM II): A Multicenter, Randomized, Controlled Trial
Authors:
- Tareq Kass-HoutTKTareq Kass-Hout
- Chung-Huan J. SunCSChung-Huan J. Sun
- Albert YooAYAlbert Yoo
- Osama O. ZaidatOZOsama O. Zaidat
- Syed F. ZaidiSZSyed F. Zaidi
- Alex Bou CheblACAlex Bou Chebl
- Eugene LinELEugene Lin
- Alhamza Al-BayatiAAAlhamza Al-Bayati
- Neeraj BadjatiaNBNeeraj Badjatia
- David LiebeskindDLDavid Liebeskind
- 9 October 2026
- journal article
- Published by Wolters Kluwer Health in Stroke
Abstract
BACKGROUND: Hypothermia reduces ischemic injury in preclinical stroke models, yet translation into the clinical setting remains challenging. We aimed to assess the feasibility of inducing adjuvant systemic hypothermia among patients with large-vessel occlusion stroke during mechanical thrombectomy. METHODS: This was a phase II randomized feasibility-controlled trial involving 10 sites in the United States, conducted between May 2019 and May 2024. All eligible patients had confirmed proximal middle cerebral artery or internal carotid artery occlusions, an Alberta Stroke Program Early Computed Tomography Score of 6 to 10, and symptom onset within 24 hours. Patients underwent mechanical thrombectomy and were randomly assigned to either treatment with adjuvant hypothermia using a novel intravascular cooling catheter or standard of care. The primary feasibility end points were the ability to achieve a target temperature of P =0.70). Final infarct volumes were numerically lower in the hypothermia treatment arm (hypothermia: 11 cm 3 [IQR, 5–42] versus control: 30 cm 3 [IQR, 6–80]; P =0.13), with no significant differences in the rates of hemorrhagic conversion or pneumonia. There was a higher number of serious adverse events in the hypothermia arm (45.5% versus 24.2%; P =0.12), although the trial was not powered for differences in serious adverse events or clinical efficacy. CONCLUSIONS: This is the first clinical trial to demonstrate the feasibility of early and rapid systemic hypothermia as an adjunct therapy during mechanical thrombectomy without delaying time to reperfusion. The potential impact on infarct volumes and serious adverse events, however, warrants further investigation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03804060.Keywords
This publication has 25 references indexed in Scilit:
- Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trialThe Lancet Neurology, 2024
- Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trialThe Lancet, 2020
- Resilience to Injury: A New Approach to Neuroprotection?Neurotherapeutics, 2020
- Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trialsThe Lancet, 2016
- Prehospital Use of Magnesium Sulfate as Neuroprotection in Acute StrokeNew England Journal of Medicine, 2015
- Neuroprotective mechanisms of hypothermia in brain ischaemiaNature Reviews Neuroscience, 2012
- Therapeutic Targets for Neuroprotection in Acute Ischemic Stroke: Lost in Translation?Antioxidants & Redox Signaling, 2011
- NXY-059 for the Treatment of Acute Ischemic StrokeNew England Journal of Medicine, 2007
- Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysisBrain, 2007
- Intravascular Cooling in the Treatment of Stroke (ICTuS): Early Clinical ExperienceJournal of Stroke and Cerebrovascular Diseases, 2005